Puma Biotechnology, Inc. Overview
Pro stress-test →Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib used to treat early-stage HER2-overexpressed/amplified breast cancer and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Strategic Profile
Pro stress-test →Puma demonstrated strong Q4 2025 commercial momentum with total revenue of $75.5M and product revenue of $59.9M, guiding 2026 net NERLYNX product revenue of $194M–$198M. The company is developing alisertib, a small molecule inhibitor of aurora kinase A for multiple cancer indications including breast cancer, small cell lung cancer, and head and neck cancer.
Competitive Landscape
Pro stress-test →Puma competes in the HER2-positive breast cancer treatment market against established players like Roche/Genentech (Herceptin, Perjeta), AstraZeneca, and others. The company's NERLYNX addresses a specific indication for extended adjuvant treatment post-trastuzumab, differentiating from competitors. Alisertib pipeline development positions Puma to enter broader oncology markets if trials succeed.
Industry Context
Puma Biotechnology, Inc. operates in Biopharmaceutical - Oncology.
Key facts
Founded: 2010 · Headquarters: Los Angeles, US · Revenue: $212M · Market cap: $382.96M